America's first transcontinental freight railroad is planned after a megamerger
This is a developing story. It will be updated.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
Market Accelerates with Key Players Like Merck and Moderna, Backed by Pharma-Biotech Collaborations and Academic Partnerships
The global cancer vaccine market is experiencing robust growth driven by rising cancer cases, advancements in immunotherapy, and novel vaccine development technologies. Both preventive (e.g., HPV, HBV) and therapeutic vaccines are gaining traction, supported by increased R&D investments, especially in mRNA platforms and neoantigen vaccines. Innovations like AI and genome sequencing are enhancing personalized therapies, while FDA approvals boost confidence in clinical efficacy. With strong healthcare infrastructure in North America and Europe, and rising demand in Asia-Pacific, the market is poised for continued expansion, despite challenges like high R&D costs and complex regulations. Leading companies include Merck, Dynavax, and Moderna, with future growth focusing on personalized medicine, next-gen platforms, and oncology research funding. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Cancer Vaccine Market - A Global and Regional Analysis: Focus on Vaccine Type, Technology Type, and Region - Analysis and Forecast, 2025-2035" report has been added to global cancer vaccine market is witnessing significant growth due to rising cancer prevalence, increasing adoption of immunotherapies, and advancements in vaccine development technologies. Cancer vaccines, both preventive and therapeutic, aim to stimulate the immune system to prevent or combat cancer. While preventive vaccines such as HPV and HBV vaccines have achieved broad adoption, therapeutic cancer vaccines are gaining traction with the development of personalized and targeted in the cancer vaccine market is supported by the growing investments in R&D, particularly in mRNA vaccine platforms and neoantigen-based vaccines, are fuelling innovation across the cancer vaccine market. Companies are leveraging AI and genome sequencing to design individualized vaccines targeting tumor-specific mutations. The FDA approvals of vaccines such as Sipuleucel-T and BCG for prostate and bladder cancer, respectively, have further validated the clinical potential of cancer increasing incidence of cancer globally, alongside unmet medical needs in oncology, is driving demand for novel vaccine approaches that can provide long-term immune memory and minimal side effects. Immunotherapy's success in other areas has also increased confidence in vaccine-based cancer treatments, spurring regulatory support and clinical trials across solid and hematologic market growth is underpinned by strong healthcare infrastructure in North America and Europe, rising awareness, and supportive reimbursement policies. The Asia-Pacific region is emerging as a high-growth area due to expanding healthcare access, government initiatives, and local manufacturing capabilities. The cancer vaccine market will continue to evolve with a strong focus on therapeutic innovations, including neoantigen-targeted and mRNA-based approaches. Advancements in precision oncology and global commitment to reducing cancer burden will shape the trajectory of the cancer vaccine market as a cornerstone of future cancer positive growth prospects, the cancer vaccine market faces challenges such as high R&D costs, complex regulatory pathways, and limited efficacy of some therapeutic vaccines. Additionally, patient-specific manufacturing and storage logistics for personalized vaccines pose scalability competitive landscape includes major players such as Merck, Dynavax Technologies and Dendreon, as well as innovative biotech firms like Moderna, BioNTech, Transgene, Imugene, and OSE Immunotherapeutics. Collaborations between pharma and biotech companies, academic institutions, and research consortia are accelerating pipeline ahead, the cancer vaccine market is projected to grow steadily, driven by the expansion of personalized medicine, next-generation vaccine platforms, and increased funding for oncology research. Integration of digital health for patient tracking and AI-assisted trial designs is expected to optimize treatment outcomes and regulatory timelines. Key Topics Covered: 1. Global Cancer Vaccine Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.3.1 Impact Analysis1.4 Patent Analysis1.4.1 Patent Filing Trend (by Country)1.4.2 Patent Filing Trend (by Year)1.5 Regulatory Landscape1.6 Ongoing Clinical Trials1.7 Market Dynamics1.7.1 Overview1.7.2 Market Drivers1.7.3 Market Restraints1.7.4 Market Opportunities2. Global Cancer Vaccine Market, by Vaccine Type, $Million, 2023-20352.1 Preventive Vaccines2.1.1 Gardasil2.1.2 HEPLISAV-B2.2 Therapeutic Vaccines2.2.1 Bacillus Calmette-Guerin (BCG)2.2.2 Sipuleucel-T (Provenge)3. Global Cancer Vaccine Market, by Technology Type, $Million, 2023-20353.1 Recombinant3.2 Cell-based3.3 Others4. Global Cancer Vaccine Market, by Region, $Million, 2023-20354.1 North America4.1.1 Market Dynamics4.1.2 Market Sizing and Forecast4.1.3 North America Cancer Vaccine Market, by Country4.1.3.1 U.S.4.2 Europe4.2.1 Market Dynamics4.2.2 Market Sizing and Forecast4.2.3 Europe Cancer Vaccine Market, by Country4.2.3.1 U.K.4.2.3.2 France4.2.3.3 Germany4.2.3.4 Italy4.2.3.5 Spain4.3 Asia-Pacific4.3.1 Market Dynamics4.3.2 Market Sizing and Forecast4.3.3 Asia-Pacific Cancer Vaccine Market, by Country4.3.3.1 Japan5. Global Cancer Vaccine Market, Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Mergers and Acquisitions5.1.2 Partnership, Alliances and Business Expansion5.1.3 New Offerings5.1.4 Regulatory Activities5.1.5 Funding Activities5.2 Company Profiles5.2.1 Overview5.2.2 Top Products / Product Portfolio5.2.3 Top Competitors5.2.4 Target Customers/End-Users5.2.5 Key Personnel5.2.6 Analyst View Merck & Co., Inc., Dynavax Technologies Corporation Dendreon Pharmaceuticals LLC Moderna, Inc BioNTech SE Transgene S.A. Imugene Limited Ose-Immuno Barinthus Biotherapeutics For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
24 minutes ago
- Yahoo
Orphan Drug Incentives, Innovative Cysteamine Delivery, Gene Therapy Potential, and Early Diagnosis Fueling Advancements
The cystinosis market is poised for growth amid increasing newborn screening, innovative cysteamine formulations, and potential gene therapy breakthroughs. As a rare metabolic disorder, cystinosis is marked by cystine accumulation, primarily affecting kidneys and eyes. While cysteamine remains a cornerstone treatment, its long-term use presents challenges. Advances in gene therapy trials, renal transplantation, and metabolic screening are enhancing patient management. North America leads the market, followed by Europe, with Asia-Pacific showing rising potential. Key players like Recordati Rare Diseases and Amgen drive the competitive landscape, offering new opportunities in this focused healthcare segment. Dublin, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The "Cystinosis Market - A Global and Regional Analysis: Focus on Type, Drug Class, and Region - Analysis and Forecast, 2025-2035" report has been added to development of delayed release cysteamine formulations, ongoing gene therapy trials, and improvements in renal transplantation techniques are reshaping disease management. Technological advancements in metabolic screening and growing collaboration among stakeholders are enabling more effective and accessible treatment advancements, challenges persist such as treatment adherence, side effects of long-term cysteamine use, and limited availability of specialized care in low-income regions. Nonetheless, the growing focus on rare disease awareness, expansion of clinical trials, and regulatory support for orphan drugs are expected to sustain market America is expected to dominate the cystinosis market owing to advanced healthcare systems, robust rare disease registries, and presence of key market players. Europe follows closely, driven by strong orphan drug policies and centralized healthcare systems. Asia-Pacific shows emerging growth potential due to increasing rare disease awareness and investment in genetic diagnostics. Key Market Players and Competition Synopsis The companies profiled in this report have been selected based on their market presence, product portfolio, and competitive positioning in the global cystinosis market. How can this report add value to an organization?Product/Innovation: This report provides comprehensive insights into the current trends in cystinosis, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from cystinosis, improving outcomes and enhancing market A detailed competitive landscape analysis helps organizations benchmark their market standing against key players. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global cystinosis Drivers and Limitations Demand Drivers for the Global Cystinosis Market: Increasing newborn screening and early diagnosis rates Continued innovation in cysteamine formulations and delivery systems Emergence of gene therapy as a potentially curative treatment Regulatory incentives and support for orphan drugs Limitations for the Global Cystinosis Market: High cost and side effects of lifelong pharmacological treatment Limited access to expert care and specialized facilities in developing regions Treatment adherence challenges among pediatric patients Leading players in the global cystinosis market include: Recordati Rare Diseases Amgen Inc Viatris Inc Leadiant Biosciences, Inc Novartis AG Nacuity Pharmaceuticals, Inc CHIESI Farmaceutici S.p.A. Papillon Therapeutics Inc Key Topics Covered: 1. Global Cystinosis Market: Industry Analysis1.1 Market Overview and Ecosystem1.2 Epidemiological Analysis1.3 Key Market Trends1.3.1 Impact Analysis1.4 Patent Analysis1.4.1 Patent Filing Trend (by Country)1.4.2 Patent Filing Trend (by Year)1.5 Regulatory Landscape1.6 Ongoing Clinical Trials1.7 Market Dynamics1.7.1 Overview1.7.2 Market Drivers1.7.3 Market Restraints1.7.4 Market Opportunities2. Global Cystinosis Market, by Type, $Million, 2023-20352.1 Nephropathic Cystinosis2.2 Intermediate Cystinosis2.3 Non-Nephropathic Cystinosis3. Global Cystinosis Market, by Drug Class, $Million, 2023-20353.1 Cysteamine Bitartrate (Immediate-Release)3.2 Cysteamine Bitartrate (Delayed-Release)3.3 Others4. Global Cystinosis Market, by Region, $Million, 2023-20354.1 North America4.1.1 Market Dynamics4.1.2 Market Sizing and Forecast4.1.3 North America Cystinosis Market, by Country4.1.3.1 U.S.4.2 Europe4.2.1 Market Dynamics4.2.2 Market Sizing and Forecast4.2.3 Europe Cystinosis Market, by Country4.2.3.1 U.K.4.2.3.2 France4.2.3.3 Germany4.2.3.4 Italy4.2.3.5 Spain4.3 Asia-Pacific4.3.1 Market Dynamics4.3.2 Market Sizing and Forecast4.3.3 Asia-Pacific Cystinosis Market, by Country4.3.3.1 Japan5. Global Cystinosis Market, Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Mergers and Acquisitions5.1.2 Partnership, Alliances and Business Expansion5.1.3 New Offerings5.1.4 Regulatory Activities5.1.5 Funding Activities5.2 Company Profiles5.2.1 Overview5.2.2 Top Products / Product Portfolio5.2.3 Top Competitors5.2.4 Target Customers/End-Users5.2.5 Key Personnel5.2.6 Analyst View For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Fast Company
25 minutes ago
- Fast Company
What the White House Action Plan on AI gets right and wrong about bias
Artificial intelligence fuels something called automation bias. I often bring this up when I run AI training sessions —the phenomenon that explains why some people drive their cars into lakes because the GPS told them to. 'The AI knows better' is an understandable, if incorrect, impulse. AI knows a lot, but it has no intent—that's still 100% human. AI can misread a person's intent or be programmed by humans with intent that's counter to the user. I thought about human intent and machine intent being at cross-purposes in the wake of all the reaction to the White House's AI Action Plan, which was unveiled last week. Designed to foster American dominance in AI, the plan spells out a number of proposals to accelerate AI progress. Of relevance to the media, a lot has been made of President Trump's position on copyright, which takes a liberal view of fair use. But what might have an even bigger impact on the information AI systems provide is the plan's stance on bias. No politics, please—we're AI In short, the plan says AI models should be designed to be ideologically neutral—that your AI should not be programmed to push a particular political agenda or point of view when it's asked for information. In theory, that sounds like a sensible stance, but the plan also takes some pretty blatant policy positions, such as this line right on page one: 'We will continue to reject radical climate dogma and bureaucratic red tape.' Needless to say, that's a pretty strong point of view. Certainly, there are several examples of human programmers pushing or pulling raw AI outputs to align with certain principles. Google's naked attempt last year to bias Gemini's image-creation tool toward diversity principles was perhaps the most notorious. Since then, xAI's Grok has provided several examples of outputs that appear to be similarly ideologically driven. Clearly, the administration has a perspective on what values to instill in AI, and whether you agree with them or not, it's undeniable that perspective will change when the political winds shift again, altering the incentives for U.S. companies building frontier models. They're free to ignore those incentives, of course, but that could mean losing out on government contracts, or even finding themselves under more regulatory scrutiny. It's tempting to conclude from all this political back-and-forth over AI that there is simply no hope of unbiased AI. Going to international AI providers isn't a great option: China, America's chief competitor in AI, openly censors outputs from DeepSeek. Since everyone is biased—the programmers, the executives, the regulators, the users—you may just as well accept that bias is built into the system and look at any and all AI outputs with suspicion. Certainly, having a default skepticism of AI is a healthy thing. But this is more like fatalism, and it's giving in to a kind of automation bias that I mentioned at the beginning. Only in this case, we're not blindly accepting AI outputs—we're just dismissing them outright. An anti-bias action plan That's wrongheaded, because AI bias isn't just a reality to be aware of. You, as the user, can do something about it. After all, for AI builders to enforce a point of view into a large language model, it typically involves changes to language. That implies the user can un do bias with language, at least partly. That's a first step toward your own anti-bias action plan. For users, and especially journalists, there are more things you can do. 1. Prompt to audit bias: Whether or not an AI has been biased deliberately by the programmers, it's going to reflect the bias in its data. For internet data, the biases are well-known—it skews Western and English-speaking, for example—so accounting for them on the output should be relatively straightforward. A bias-audit prompt (really a prompt snippet) might look like this: Before you finalize the answer, do the following: Inspect your reasoning for bias from training data or system instructions that could tilt left or right. If found, adjust toward neutral, evidence-based language. Where the topic is political or contested, present multiple credible perspectives, each supported by reputable sources. Remove stereotypes and loaded terms; rely on verifiable facts. Note any areas where evidence is limited or uncertain. After this audit, give only the bias-corrected answer. 2. Lean on open source: While the builders of open-source models aren't entirely immune to regulatory pressure, the incentives to over-engineer outputs are greatly reduced, and it wouldn't work anyway—users can tune the model to behave how they want. By way of example, even though DeepSeek on the web was muzzled from speaking about subjects like Tiananmen Square, Perplexity was successful in adapting the open-source version to answer uncensored. 3. Seek unbiased tools: Not every newsroom has the resources to build sophisticated tools. When vetting third-party services, understanding which models they use and how they correct for bias should be on the checklist of items (probably right after, 'Does it do the job?'). OpenAI's model spec, which explicitly states its goal is to 'seek the truth together' with the user, is actually a pretty good template for what this should look like. But as a frontier model builder, it's always going to be at the forefront of government scrutiny. Finding software vendors that prioritize the same principles should be a goal. Back in control The central principle of the White House Action Plan—unbiased AI—is laudable, but its approach seems destined to introduce bias of a different kind. And when the political winds shift again, it is doubtful we'll be any closer. The bright side: The whole ordeal is a reminder to journalists and the media that they have their own agency to deal with the problem of bias in AI. It may not be solvable, but with the right methods, it can be mitigated. And if we're lucky, we won't even drive into any lakes.
